| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Immunoglobulin Gm Allotypes | 78 | 2022 | 103 | 13.520 |
Why?
|
| Immunoglobulin G | 71 | 2022 | 481 | 9.260 |
Why?
|
| Receptors, IgG | 25 | 2021 | 94 | 9.230 |
Why?
|
| Cytomegalovirus | 12 | 2019 | 63 | 4.980 |
Why?
|
| Genotype | 53 | 2022 | 786 | 4.890 |
Why?
|
| Immunoglobulin Allotypes | 73 | 2014 | 82 | 4.750 |
Why?
|
| Immunoglobulin Km Allotypes | 25 | 2021 | 34 | 4.680 |
Why?
|
| Cytomegalovirus Infections | 11 | 2019 | 69 | 4.170 |
Why?
|
| Polymorphism, Genetic | 36 | 2022 | 301 | 3.740 |
Why?
|
| Genetic Predisposition to Disease | 38 | 2019 | 786 | 3.590 |
Why?
|
| Immunoglobulin kappa-Chains | 17 | 2015 | 30 | 3.500 |
Why?
|
| Immunoglobulins | 13 | 2017 | 97 | 2.870 |
Why?
|
| Immunity, Humoral | 10 | 2022 | 42 | 2.860 |
Why?
|
| Herpesvirus 1, Human | 5 | 2022 | 30 | 2.640 |
Why?
|
| Genes, Immunoglobulin | 12 | 2019 | 56 | 2.630 |
Why?
|
| Antibodies, Viral | 10 | 2022 | 110 | 2.630 |
Why?
|
| Immunoglobulin gamma-Chains | 11 | 2022 | 12 | 2.450 |
Why?
|
| Breast Neoplasms | 11 | 2018 | 1536 | 2.420 |
Why?
|
| Alzheimer Disease | 6 | 2022 | 565 | 2.350 |
Why?
|
| Alleles | 36 | 2022 | 386 | 2.220 |
Why?
|
| Scleroderma, Systemic | 19 | 2006 | 446 | 1.860 |
Why?
|
| Humans | 228 | 2022 | 68618 | 1.750 |
Why?
|
| Polymorphism, Single Nucleotide | 9 | 2020 | 627 | 1.740 |
Why?
|
| Membrane Glycoproteins | 5 | 2022 | 370 | 1.730 |
Why?
|
| Immunoglobulin Heavy Chains | 17 | 2015 | 72 | 1.710 |
Why?
|
| Viral Proteins | 4 | 2016 | 150 | 1.690 |
Why?
|
| Mucin-1 | 4 | 2017 | 35 | 1.670 |
Why?
|
| Schizophrenia | 4 | 2017 | 206 | 1.560 |
Why?
|
| HIV Infections | 9 | 2022 | 791 | 1.480 |
Why?
|
| HIV-1 | 6 | 2022 | 177 | 1.410 |
Why?
|
| Hepatitis C | 7 | 2011 | 114 | 1.410 |
Why?
|
| Tumor Necrosis Factor-alpha | 13 | 2008 | 626 | 1.400 |
Why?
|
| Epistasis, Genetic | 8 | 2018 | 32 | 1.380 |
Why?
|
| Case-Control Studies | 26 | 2022 | 1553 | 1.360 |
Why?
|
| HLA Antigens | 18 | 2019 | 82 | 1.260 |
Why?
|
| Genetic Variation | 8 | 2018 | 220 | 1.250 |
Why?
|
| Hepacivirus | 8 | 2011 | 90 | 1.240 |
Why?
|
| Antibodies, Monoclonal | 6 | 2022 | 511 | 1.200 |
Why?
|
| Interleukin-1 | 10 | 2009 | 86 | 1.160 |
Why?
|
| Immunotherapy | 4 | 2018 | 215 | 1.120 |
Why?
|
| Viral Envelope Proteins | 3 | 2015 | 43 | 1.060 |
Why?
|
| ErbB Receptors | 2 | 2020 | 239 | 1.060 |
Why?
|
| Autoantibodies | 18 | 2016 | 434 | 1.050 |
Why?
|
| Immunoglobulin Fc Fragments | 4 | 2014 | 11 | 1.040 |
Why?
|
| Female | 100 | 2021 | 38074 | 1.020 |
Why?
|
| Antibody Formation | 13 | 2021 | 93 | 1.000 |
Why?
|
| Genetic Loci | 3 | 2013 | 59 | 0.960 |
Why?
|
| Phenotype | 49 | 2019 | 947 | 0.950 |
Why?
|
| Autoimmune Diseases | 7 | 2012 | 186 | 0.950 |
Why?
|
| Genome-Wide Association Study | 6 | 2020 | 240 | 0.920 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 3 | 2015 | 17 | 0.900 |
Why?
|
| Male | 98 | 2021 | 37321 | 0.890 |
Why?
|
| Neuroblastoma | 3 | 2020 | 109 | 0.890 |
Why?
|
| Adult | 84 | 2022 | 21403 | 0.880 |
Why?
|
| Antibodies, Protozoan | 3 | 2018 | 15 | 0.870 |
Why?
|
| Flagellin | 2 | 2014 | 2 | 0.860 |
Why?
|
| Haplotypes | 19 | 2014 | 174 | 0.850 |
Why?
|
| Gene Frequency | 28 | 2019 | 207 | 0.840 |
Why?
|
| Prostatic Neoplasms | 3 | 2013 | 778 | 0.840 |
Why?
|
| Receptors, KIR | 3 | 2017 | 3 | 0.790 |
Why?
|
| Lung Neoplasms | 4 | 2015 | 1173 | 0.790 |
Why?
|
| Middle Aged | 60 | 2020 | 21147 | 0.780 |
Why?
|
| Receptors, Immunologic | 2 | 2022 | 72 | 0.780 |
Why?
|
| Pseudomonas Infections | 3 | 2021 | 83 | 0.760 |
Why?
|
| Apolipoproteins E | 2 | 2022 | 92 | 0.750 |
Why?
|
| Antigens, Protozoan | 3 | 2010 | 10 | 0.750 |
Why?
|
| Brazil | 8 | 2018 | 48 | 0.750 |
Why?
|
| Lupus Erythematosus, Systemic | 11 | 2007 | 756 | 0.750 |
Why?
|
| Glioblastoma | 2 | 2014 | 219 | 0.710 |
Why?
|
| Antigens, Differentiation | 3 | 2005 | 49 | 0.710 |
Why?
|
| Genetic Association Studies | 4 | 2016 | 103 | 0.690 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2014 | 300 | 0.690 |
Why?
|
| Multiple Sclerosis | 6 | 2013 | 132 | 0.690 |
Why?
|
| Antigens, Neoplasm | 4 | 2014 | 132 | 0.680 |
Why?
|
| Biomarkers | 6 | 2020 | 1593 | 0.680 |
Why?
|
| Cystic Fibrosis | 4 | 2021 | 283 | 0.680 |
Why?
|
| Killer Cells, Natural | 4 | 2017 | 94 | 0.670 |
Why?
|
| Parkinson Disease | 1 | 2022 | 272 | 0.670 |
Why?
|
| Japan | 6 | 2017 | 68 | 0.650 |
Why?
|
| Carrier Proteins | 4 | 2020 | 597 | 0.640 |
Why?
|
| Homozygote | 10 | 2020 | 119 | 0.640 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2020 | 151 | 0.630 |
Why?
|
| Cognitive Dysfunction | 2 | 2019 | 176 | 0.630 |
Why?
|
| Hepatitis C Antibodies | 3 | 2008 | 19 | 0.620 |
Why?
|
| Viral Core Proteins | 2 | 2008 | 12 | 0.610 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 1 | 2017 | 10 | 0.610 |
Why?
|
| Herpesvirus 4, Human | 3 | 2009 | 30 | 0.610 |
Why?
|
| Receptor, ErbB-2 | 3 | 2013 | 129 | 0.600 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2020 | 332 | 0.600 |
Why?
|
| HIV Seropositivity | 1 | 2018 | 66 | 0.600 |
Why?
|
| Biomarkers, Tumor | 2 | 2011 | 508 | 0.590 |
Why?
|
| Genetic Markers | 14 | 2012 | 144 | 0.570 |
Why?
|
| Aged | 32 | 2019 | 14862 | 0.570 |
Why?
|
| Cyclin B1 | 2 | 2014 | 7 | 0.550 |
Why?
|
| Hepatitis C, Chronic | 3 | 2007 | 86 | 0.540 |
Why?
|
| Indians, South American | 8 | 2000 | 12 | 0.540 |
Why?
|
| Membrane Proteins | 3 | 2018 | 617 | 0.530 |
Why?
|
| Occupational Exposure | 3 | 2015 | 122 | 0.520 |
Why?
|
| Gene-Environment Interaction | 1 | 2015 | 31 | 0.510 |
Why?
|
| Lymphotoxin-alpha | 5 | 2004 | 9 | 0.500 |
Why?
|
| Aged, 80 and over | 14 | 2015 | 4848 | 0.500 |
Why?
|
| HLA-C Antigens | 3 | 2019 | 8 | 0.500 |
Why?
|
| Occupational Diseases | 1 | 2015 | 68 | 0.500 |
Why?
|
| HLA-DQ Antigens | 6 | 2011 | 19 | 0.490 |
Why?
|
| Guillain-Barre Syndrome | 2 | 2005 | 8 | 0.480 |
Why?
|
| Malaria, Falciparum | 3 | 2011 | 10 | 0.480 |
Why?
|
| Neuronal Apoptosis-Inhibitory Protein | 1 | 2014 | 3 | 0.480 |
Why?
|
| Toll-Like Receptor 5 | 1 | 2014 | 4 | 0.480 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2014 | 15 | 0.480 |
Why?
|
| Onchocerciasis | 2 | 2009 | 4 | 0.460 |
Why?
|
| Risk Factors | 19 | 2020 | 5731 | 0.460 |
Why?
|
| Herpes Simplex | 2 | 2015 | 35 | 0.450 |
Why?
|
| AIDS Vaccines | 1 | 2013 | 7 | 0.440 |
Why?
|
| Linkage Disequilibrium | 8 | 2013 | 91 | 0.440 |
Why?
|
| Bacterial Vaccines | 12 | 2000 | 32 | 0.440 |
Why?
|
| Young Adult | 12 | 2021 | 5717 | 0.440 |
Why?
|
| Alopecia Areata | 4 | 1999 | 17 | 0.440 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 9 | 2018 | 507 | 0.430 |
Why?
|
| Periodontitis | 5 | 1999 | 47 | 0.420 |
Why?
|
| B-Lymphocytes | 4 | 2013 | 329 | 0.420 |
Why?
|
| Immunoglobulin Fab Fragments | 2 | 2012 | 48 | 0.420 |
Why?
|
| Herpes Labialis | 1 | 2012 | 1 | 0.420 |
Why?
|
| Chromosomes, Human, Pair 21 | 1 | 2012 | 9 | 0.420 |
Why?
|
| Protein Binding | 5 | 2016 | 1027 | 0.410 |
Why?
|
| Herpesvirus 2, Human | 1 | 2012 | 10 | 0.410 |
Why?
|
| Chromosomes, Human, Pair 2 | 4 | 2009 | 14 | 0.410 |
Why?
|
| Herpes Genitalis | 1 | 2012 | 12 | 0.410 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2012 | 34 | 0.400 |
Why?
|
| Carcinoma | 1 | 2013 | 215 | 0.400 |
Why?
|
| Malaria | 2 | 2013 | 26 | 0.400 |
Why?
|
| Chromosomes, Human, Pair 14 | 5 | 2019 | 16 | 0.390 |
Why?
|
| Drug Resistance | 1 | 2012 | 223 | 0.390 |
Why?
|
| HIV | 1 | 2011 | 56 | 0.390 |
Why?
|
| Antibodies, Neutralizing | 5 | 2022 | 46 | 0.390 |
Why?
|
| Glomerulonephritis, Membranous | 1 | 2011 | 8 | 0.390 |
Why?
|
| Antigens, Viral | 3 | 2009 | 35 | 0.390 |
Why?
|
| Epitopes, B-Lymphocyte | 1 | 2011 | 2 | 0.380 |
Why?
|
| Plasmodium falciparum | 2 | 2009 | 45 | 0.380 |
Why?
|
| Antibodies | 6 | 2014 | 241 | 0.380 |
Why?
|
| Neoplasm Staging | 4 | 2016 | 800 | 0.370 |
Why?
|
| Antigens, Bacterial | 8 | 2021 | 54 | 0.370 |
Why?
|
| Heterozygote | 10 | 2019 | 174 | 0.370 |
Why?
|
| Adjuvants, Immunologic | 1 | 2011 | 63 | 0.370 |
Why?
|
| Genes, Immunoglobulin Heavy Chain | 1 | 2010 | 6 | 0.370 |
Why?
|
| Plasmodium vivax | 1 | 2010 | 2 | 0.370 |
Why?
|
| Animals | 17 | 2020 | 20881 | 0.370 |
Why?
|
| Adolescent | 33 | 2015 | 8912 | 0.370 |
Why?
|
| Genes, MHC Class II | 7 | 1999 | 29 | 0.370 |
Why?
|
| Malaria, Vivax | 1 | 2010 | 3 | 0.370 |
Why?
|
| HIV Antibodies | 4 | 2022 | 28 | 0.370 |
Why?
|
| Disease Susceptibility | 13 | 2015 | 179 | 0.360 |
Why?
|
| Tumor Microenvironment | 1 | 2011 | 213 | 0.360 |
Why?
|
| Graft vs Host Disease | 1 | 2012 | 163 | 0.350 |
Why?
|
| Antibody Affinity | 3 | 2016 | 26 | 0.350 |
Why?
|
| Cytochrome P-450 Enzyme System | 2 | 2017 | 62 | 0.350 |
Why?
|
| Autoimmunity | 2 | 2013 | 118 | 0.340 |
Why?
|
| Onchocerca volvulus | 1 | 2009 | 3 | 0.330 |
Why?
|
| Antiviral Agents | 1 | 2011 | 211 | 0.330 |
Why?
|
| Gangliosides | 2 | 2005 | 29 | 0.320 |
Why?
|
| Immunoglobulin Constant Regions | 4 | 2003 | 12 | 0.320 |
Why?
|
| Antibodies, Bacterial | 12 | 2000 | 90 | 0.320 |
Why?
|
| Dermatomyositis | 7 | 2008 | 31 | 0.310 |
Why?
|
| Cohort Studies | 4 | 2018 | 2358 | 0.310 |
Why?
|
| Stomach Neoplasms | 1 | 2008 | 64 | 0.300 |
Why?
|
| Colorectal Neoplasms | 1 | 2012 | 561 | 0.290 |
Why?
|
| Typhoid Fever | 2 | 1997 | 2 | 0.280 |
Why?
|
| Gliadin | 3 | 2016 | 5 | 0.280 |
Why?
|
| Multigene Family | 3 | 2004 | 93 | 0.270 |
Why?
|
| Viral Matrix Proteins | 1 | 2006 | 10 | 0.270 |
Why?
|
| Solvents | 3 | 2001 | 109 | 0.270 |
Why?
|
| Immunogenetics | 3 | 2019 | 8 | 0.260 |
Why?
|
| Tryptophan | 3 | 2018 | 65 | 0.260 |
Why?
|
| Child | 23 | 2016 | 6405 | 0.250 |
Why?
|
| Sarcoidosis | 2 | 2003 | 77 | 0.250 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2005 | 24 | 0.250 |
Why?
|
| Polysaccharides, Bacterial | 12 | 2000 | 31 | 0.250 |
Why?
|
| Sjogren's Syndrome | 1 | 2004 | 18 | 0.240 |
Why?
|
| Recombinant Proteins | 3 | 2015 | 742 | 0.240 |
Why?
|
| Phosphoproteins | 1 | 2006 | 202 | 0.240 |
Why?
|
| Interleukin-10 | 1 | 2005 | 144 | 0.240 |
Why?
|
| Capsid Proteins | 1 | 2004 | 27 | 0.240 |
Why?
|
| Chaperonin 60 | 1 | 2004 | 10 | 0.230 |
Why?
|
| Chaperonins | 1 | 2004 | 4 | 0.230 |
Why?
|
| Immunoglobulin Isotypes | 5 | 1996 | 28 | 0.230 |
Why?
|
| Diabetes Mellitus, Type 2 | 5 | 2010 | 1085 | 0.230 |
Why?
|
| Myositis | 3 | 2016 | 24 | 0.230 |
Why?
|
| Host-Pathogen Interactions | 3 | 2019 | 69 | 0.220 |
Why?
|
| Microfilament Proteins | 2 | 2001 | 102 | 0.220 |
Why?
|
| Neoplasm Grading | 2 | 2013 | 111 | 0.220 |
Why?
|
| Genetic Linkage | 7 | 2009 | 90 | 0.210 |
Why?
|
| Apolipoprotein E4 | 1 | 2022 | 31 | 0.210 |
Why?
|
| Cetuximab | 2 | 2012 | 19 | 0.210 |
Why?
|
| Interleukin-6 | 1 | 2004 | 330 | 0.200 |
Why?
|
| Epitopes | 6 | 2008 | 146 | 0.200 |
Why?
|
| Odds Ratio | 4 | 2013 | 880 | 0.200 |
Why?
|
| Cognition | 2 | 2017 | 513 | 0.200 |
Why?
|
| Immunoglobulin M | 5 | 2009 | 172 | 0.200 |
Why?
|
| Bacterial Proteins | 1 | 2004 | 245 | 0.200 |
Why?
|
| Interleukin-1beta | 4 | 2009 | 88 | 0.200 |
Why?
|
| Antibodies, Antinuclear | 5 | 2005 | 171 | 0.200 |
Why?
|
| Neutrophils | 3 | 1999 | 204 | 0.190 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 3 | 2009 | 14 | 0.190 |
Why?
|
| Campylobacter Infections | 3 | 2005 | 7 | 0.190 |
Why?
|
| Immunity, Cellular | 3 | 2019 | 80 | 0.190 |
Why?
|
| Chromosome Mapping | 4 | 2013 | 188 | 0.180 |
Why?
|
| Vaccination | 5 | 2000 | 189 | 0.180 |
Why?
|
| Logistic Models | 3 | 2017 | 1420 | 0.180 |
Why?
|
| Coronary Disease | 2 | 2004 | 358 | 0.180 |
Why?
|
| HLA-B Antigens | 2 | 2019 | 7 | 0.180 |
Why?
|
| CTLA-4 Antigen | 3 | 2005 | 45 | 0.180 |
Why?
|
| Receptors, KIR2DL3 | 1 | 2019 | 1 | 0.180 |
Why?
|
| Kynurenine | 2 | 2018 | 36 | 0.170 |
Why?
|
| Transforming Growth Factor beta | 1 | 2002 | 384 | 0.170 |
Why?
|
| Hepatitis B, Chronic | 1 | 2019 | 19 | 0.170 |
Why?
|
| Binding Sites, Antibody | 4 | 2011 | 34 | 0.170 |
Why?
|
| United States | 11 | 2021 | 7367 | 0.170 |
Why?
|
| HLA-DR Antigens | 7 | 2009 | 41 | 0.170 |
Why?
|
| Antigens, CD | 3 | 2005 | 230 | 0.170 |
Why?
|
| Elephantiasis, Filarial | 1 | 1999 | 1 | 0.170 |
Why?
|
| Immunoglobulin A | 6 | 2003 | 79 | 0.160 |
Why?
|
| Amyloid beta-Peptides | 1 | 2020 | 191 | 0.160 |
Why?
|
| Toxoplasmosis | 1 | 2018 | 13 | 0.160 |
Why?
|
| Tooth Movement Techniques | 2 | 2009 | 6 | 0.150 |
Why?
|
| Phenylalanine | 1 | 2018 | 22 | 0.150 |
Why?
|
| Sicily | 1 | 2017 | 1 | 0.150 |
Why?
|
| Toxoplasma | 1 | 2018 | 23 | 0.150 |
Why?
|
| HLA-DQ alpha-Chains | 5 | 2011 | 5 | 0.150 |
Why?
|
| Promoter Regions, Genetic | 4 | 2007 | 615 | 0.150 |
Why?
|
| Immunologic Surveillance | 1 | 2017 | 10 | 0.150 |
Why?
|
| RNA, Viral | 2 | 2011 | 93 | 0.150 |
Why?
|
| Rituximab | 1 | 2017 | 61 | 0.150 |
Why?
|
| Pharmacogenetics | 1 | 2017 | 47 | 0.150 |
Why?
|
| Tyrosine | 1 | 2018 | 196 | 0.150 |
Why?
|
| Cyclophosphamide | 1 | 2017 | 129 | 0.150 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 1046 | 0.140 |
Why?
|
| Impulsive Behavior | 1 | 2018 | 85 | 0.140 |
Why?
|
| Leprosy | 1 | 1997 | 1 | 0.140 |
Why?
|
| Bacterial Outer Membrane Proteins | 2 | 1994 | 21 | 0.140 |
Why?
|
| Precision Medicine | 1 | 2018 | 111 | 0.140 |
Why?
|
| Prognosis | 2 | 2013 | 2093 | 0.140 |
Why?
|
| Immune Evasion | 1 | 2016 | 19 | 0.140 |
Why?
|
| Glutens | 1 | 2016 | 10 | 0.140 |
Why?
|
| Haemophilus influenzae | 7 | 1989 | 16 | 0.140 |
Why?
|
| Mice | 5 | 2020 | 8474 | 0.140 |
Why?
|
| Psoriasis | 1 | 1997 | 46 | 0.140 |
Why?
|
| Onchocerca | 1 | 1995 | 4 | 0.130 |
Why?
|
| Antibodies, Helminth | 1 | 1995 | 2 | 0.130 |
Why?
|
| Haemophilus Infections | 6 | 2000 | 15 | 0.130 |
Why?
|
| Polymorphism, Restriction Fragment Length | 5 | 2006 | 44 | 0.130 |
Why?
|
| Coronary Vessels | 1 | 1998 | 313 | 0.130 |
Why?
|
| Age Factors | 6 | 2018 | 1864 | 0.120 |
Why?
|
| Major Histocompatibility Complex | 1 | 1995 | 34 | 0.120 |
Why?
|
| Centromere | 3 | 2006 | 15 | 0.120 |
Why?
|
| Histocompatibility Antigens Class II | 5 | 2003 | 77 | 0.120 |
Why?
|
| RNA Polymerase III | 2 | 2005 | 7 | 0.120 |
Why?
|
| Survival | 1 | 2014 | 22 | 0.120 |
Why?
|
| Blood Group Antigens | 1 | 1994 | 4 | 0.120 |
Why?
|
| Immunoglobulin Light Chains | 4 | 1998 | 19 | 0.120 |
Why?
|
| Protozoan Proteins | 2 | 2010 | 25 | 0.120 |
Why?
|
| Southeastern United States | 3 | 2004 | 281 | 0.120 |
Why?
|
| Cell Line | 2 | 2015 | 1752 | 0.120 |
Why?
|
| Disease Resistance | 1 | 2014 | 3 | 0.120 |
Why?
|
| Graft Rejection | 1 | 1998 | 458 | 0.120 |
Why?
|
| Testis | 1 | 2014 | 37 | 0.120 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2014 | 66 | 0.120 |
Why?
|
| Prospective Studies | 2 | 2021 | 3705 | 0.120 |
Why?
|
| Aging | 2 | 2019 | 911 | 0.120 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2013 | 13 | 0.120 |
Why?
|
| Neisseria meningitidis | 4 | 1988 | 10 | 0.110 |
Why?
|
| Histocompatibility Testing | 5 | 2007 | 38 | 0.110 |
Why?
|
| Sudan | 2 | 2011 | 3 | 0.110 |
Why?
|
| Pilot Projects | 1 | 2017 | 1342 | 0.110 |
Why?
|
| Child, Preschool | 15 | 2008 | 3187 | 0.110 |
Why?
|
| Vaccines, Synthetic | 1 | 2013 | 19 | 0.110 |
Why?
|
| Protein Isoforms | 1 | 2013 | 246 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 536 | 0.110 |
Why?
|
| Antibody Specificity | 2 | 2011 | 98 | 0.100 |
Why?
|
| Population Groups | 1 | 2012 | 16 | 0.100 |
Why?
|
| Drug Carriers | 1 | 2013 | 90 | 0.100 |
Why?
|
| Adenoviridae | 1 | 2013 | 295 | 0.100 |
Why?
|
| Interleukin-1alpha | 2 | 2009 | 5 | 0.100 |
Why?
|
| Genetic Vectors | 1 | 2013 | 312 | 0.100 |
Why?
|
| Gingival Crevicular Fluid | 2 | 2009 | 9 | 0.100 |
Why?
|
| Pedigree | 10 | 1999 | 159 | 0.100 |
Why?
|
| Carrier State | 2 | 2011 | 39 | 0.100 |
Why?
|
| Genetic Carrier Screening | 2 | 2006 | 25 | 0.100 |
Why?
|
| Trastuzumab | 1 | 2011 | 17 | 0.100 |
Why?
|
| Asymptomatic Diseases | 1 | 2011 | 43 | 0.100 |
Why?
|
| Polymerase Chain Reaction | 6 | 2006 | 492 | 0.100 |
Why?
|
| Myasthenia Gravis | 3 | 1999 | 17 | 0.100 |
Why?
|
| Immunophenotyping | 2 | 2015 | 110 | 0.100 |
Why?
|
| Disease Outbreaks | 2 | 2009 | 83 | 0.100 |
Why?
|
| Receptors, Phospholipase A2 | 1 | 2011 | 1 | 0.100 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 3 | 2009 | 17 | 0.100 |
Why?
|
| Neoplasms | 2 | 2013 | 1667 | 0.100 |
Why?
|
| Connective Tissue Diseases | 1 | 1991 | 18 | 0.100 |
Why?
|
| Virus Replication | 1 | 2011 | 104 | 0.100 |
Why?
|
| Statistics, Nonparametric | 2 | 2010 | 306 | 0.100 |
Why?
|
| Ribavirin | 1 | 2011 | 27 | 0.090 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2011 | 26 | 0.090 |
Why?
|
| Interferon-alpha | 1 | 2011 | 46 | 0.090 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 1991 | 29 | 0.090 |
Why?
|
| Estonia | 1 | 2010 | 3 | 0.090 |
Why?
|
| Merozoite Surface Protein 1 | 1 | 2010 | 1 | 0.090 |
Why?
|
| Malaria Vaccines | 1 | 2010 | 4 | 0.090 |
Why?
|
| Chi-Square Distribution | 2 | 2005 | 546 | 0.090 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 1990 | 10 | 0.090 |
Why?
|
| Monomeric GTP-Binding Proteins | 2 | 2008 | 8 | 0.090 |
Why?
|
| HLA-DRB1 Chains | 6 | 2009 | 21 | 0.090 |
Why?
|
| Diabetes Mellitus, Type 1 | 3 | 1991 | 529 | 0.090 |
Why?
|
| Polyethylene Glycols | 1 | 2011 | 149 | 0.090 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2012 | 245 | 0.090 |
Why?
|
| Eosinophilia-Myalgia Syndrome | 1 | 2009 | 24 | 0.090 |
Why?
|
| Asthma | 1 | 2013 | 345 | 0.090 |
Why?
|
| Follow-Up Studies | 3 | 2013 | 3259 | 0.080 |
Why?
|
| Muscular Atrophy | 2 | 2008 | 35 | 0.080 |
Why?
|
| Polymyositis | 1 | 2008 | 5 | 0.080 |
Why?
|
| Helicobacter Infections | 1 | 2009 | 40 | 0.080 |
Why?
|
| Linear Models | 1 | 2010 | 521 | 0.080 |
Why?
|
| Helicobacter pylori | 1 | 2009 | 54 | 0.080 |
Why?
|
| Healthy Volunteers | 2 | 2019 | 78 | 0.080 |
Why?
|
| Half-Life | 3 | 2018 | 96 | 0.080 |
Why?
|
| Haemophilus Vaccines | 4 | 1989 | 6 | 0.080 |
Why?
|
| Lipodystrophy | 1 | 2008 | 3 | 0.080 |
Why?
|
| DNA Topoisomerases, Type I | 2 | 2006 | 13 | 0.080 |
Why?
|
| Dysplastic Nevus Syndrome | 1 | 1988 | 6 | 0.080 |
Why?
|
| Peroxidase | 1 | 2007 | 40 | 0.070 |
Why?
|
| Thymoma | 3 | 1999 | 14 | 0.070 |
Why?
|
| Polyneuropathies | 1 | 1987 | 6 | 0.070 |
Why?
|
| Myelin Proteins | 1 | 1987 | 21 | 0.070 |
Why?
|
| Thymus Neoplasms | 3 | 1999 | 17 | 0.070 |
Why?
|
| Demyelinating Diseases | 1 | 1987 | 57 | 0.070 |
Why?
|
| Dental Stress Analysis | 1 | 2006 | 22 | 0.070 |
Why?
|
| Risk | 3 | 2003 | 563 | 0.070 |
Why?
|
| Cell Line, Tumor | 1 | 2011 | 1851 | 0.070 |
Why?
|
| Environmental Exposure | 2 | 2016 | 269 | 0.070 |
Why?
|
| Antibody Diversity | 3 | 1993 | 7 | 0.070 |
Why?
|
| Amino Acids | 1 | 2007 | 131 | 0.070 |
Why?
|
| Bone Remodeling | 1 | 2006 | 45 | 0.070 |
Why?
|
| DNA-Directed RNA Polymerases | 1 | 2006 | 16 | 0.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2010 | 756 | 0.070 |
Why?
|
| Inflammation | 1 | 2012 | 1030 | 0.070 |
Why?
|
| Sex Factors | 7 | 2018 | 1266 | 0.070 |
Why?
|
| Growth Hormone | 2 | 1996 | 51 | 0.070 |
Why?
|
| Spondylitis, Ankylosing | 1 | 1985 | 10 | 0.070 |
Why?
|
| Colonic Polyps | 1 | 1986 | 63 | 0.070 |
Why?
|
| Charcot-Marie-Tooth Disease | 1 | 1985 | 4 | 0.060 |
Why?
|
| Streptococcus pneumoniae | 2 | 1996 | 32 | 0.060 |
Why?
|
| Incidence | 1 | 2009 | 1603 | 0.060 |
Why?
|
| Norway | 2 | 2003 | 18 | 0.060 |
Why?
|
| Chronic Disease | 4 | 2016 | 1330 | 0.060 |
Why?
|
| Salivary Glands, Minor | 1 | 2004 | 7 | 0.060 |
Why?
|
| Serologic Tests | 3 | 2018 | 46 | 0.060 |
Why?
|
| Bone Density | 2 | 1996 | 159 | 0.060 |
Why?
|
| Antibodies, Fungal | 1 | 2004 | 9 | 0.060 |
Why?
|
| Kidney Diseases | 1 | 2007 | 307 | 0.060 |
Why?
|
| North Carolina | 1 | 2005 | 224 | 0.060 |
Why?
|
| Treatment Outcome | 2 | 2020 | 7029 | 0.060 |
Why?
|
| Aspergillus fumigatus | 1 | 2004 | 27 | 0.060 |
Why?
|
| Streptococcus agalactiae | 1 | 1984 | 26 | 0.060 |
Why?
|
| HLA-DR2 Antigen | 1 | 2004 | 4 | 0.060 |
Why?
|
| Pseudomonas aeruginosa | 2 | 1997 | 133 | 0.060 |
Why?
|
| Fibrillins | 2 | 2001 | 24 | 0.060 |
Why?
|
| Fibrillin-1 | 2 | 2001 | 18 | 0.060 |
Why?
|
| Sialoglycoproteins | 1 | 2004 | 24 | 0.060 |
Why?
|
| RNA Polymerase I | 1 | 2003 | 5 | 0.060 |
Why?
|
| Infant | 10 | 2004 | 2891 | 0.060 |
Why?
|
| Exons | 1 | 2004 | 122 | 0.060 |
Why?
|
| Ecuador | 4 | 2000 | 8 | 0.060 |
Why?
|
| Skin Neoplasms | 1 | 1988 | 375 | 0.060 |
Why?
|
| Immunoglobulin Variable Region | 2 | 1980 | 40 | 0.060 |
Why?
|
| Campylobacter jejuni | 1 | 2003 | 2 | 0.060 |
Why?
|
| Enteritis | 1 | 2003 | 6 | 0.050 |
Why?
|
| Carotid Artery Diseases | 1 | 2004 | 83 | 0.050 |
Why?
|
| Molecular Mimicry | 1 | 2003 | 13 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2018 | 1745 | 0.050 |
Why?
|
| Severity of Illness Index | 3 | 2008 | 1851 | 0.050 |
Why?
|
| Introns | 1 | 2002 | 68 | 0.050 |
Why?
|
| Polymyalgia Rheumatica | 1 | 1982 | 5 | 0.050 |
Why?
|
| Giant Cell Arteritis | 1 | 1982 | 10 | 0.050 |
Why?
|
| Dependovirus | 1 | 2022 | 34 | 0.050 |
Why?
|
| Respiratory Tract Infections | 1 | 2003 | 91 | 0.050 |
Why?
|
| Models, Statistical | 1 | 2005 | 448 | 0.050 |
Why?
|
| Osteosarcoma | 1 | 1982 | 35 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2005 | 1753 | 0.050 |
Why?
|
| Gene Rearrangement, B-Lymphocyte | 2 | 1993 | 5 | 0.050 |
Why?
|
| Immunoglobulin Idiotypes | 2 | 1993 | 16 | 0.050 |
Why?
|
| Germany | 2 | 2018 | 67 | 0.050 |
Why?
|
| Job Syndrome | 1 | 2000 | 1 | 0.050 |
Why?
|
| Filariasis | 1 | 2000 | 2 | 0.050 |
Why?
|
| Obesity | 1 | 2008 | 1076 | 0.050 |
Why?
|
| Hypersensitivity, Immediate | 1 | 2000 | 13 | 0.050 |
Why?
|
| Meningococcal Infections | 1 | 2000 | 5 | 0.050 |
Why?
|
| T-Lymphocytes | 2 | 1995 | 597 | 0.050 |
Why?
|
| Streptococcal Infections | 1 | 2000 | 53 | 0.050 |
Why?
|
| Muscle Proteins | 2 | 1999 | 94 | 0.040 |
Why?
|
| Hobbies | 1 | 1999 | 4 | 0.040 |
Why?
|
| Geography | 2 | 2003 | 80 | 0.040 |
Why?
|
| Protein Kinases | 2 | 1999 | 122 | 0.040 |
Why?
|
| Meningitis, Haemophilus | 5 | 1989 | 5 | 0.040 |
Why?
|
| Twin Studies as Topic | 1 | 1999 | 3 | 0.040 |
Why?
|
| Protective Factors | 1 | 2019 | 24 | 0.040 |
Why?
|
| Dental Plaque | 1 | 1999 | 14 | 0.040 |
Why?
|
| Gingivitis | 1 | 1999 | 16 | 0.040 |
Why?
|
| Hepatitis B virus | 1 | 2019 | 23 | 0.040 |
Why?
|
| Administration, Cutaneous | 1 | 2019 | 56 | 0.040 |
Why?
|
| Environmental Health | 1 | 1999 | 23 | 0.040 |
Why?
|
| Cytokines | 1 | 2004 | 866 | 0.040 |
Why?
|
| Mouth Mucosa | 1 | 1999 | 51 | 0.040 |
Why?
|
| Diseases in Twins | 1 | 1999 | 31 | 0.040 |
Why?
|
| Isoantibodies | 1 | 1979 | 35 | 0.040 |
Why?
|
| Lipopolysaccharides | 1 | 1981 | 455 | 0.040 |
Why?
|
| Molecular Sequence Data | 3 | 1999 | 1447 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2019 | 89 | 0.040 |
Why?
|
| Philippines | 1 | 1999 | 5 | 0.040 |
Why?
|
| Genes | 2 | 1978 | 86 | 0.040 |
Why?
|
| Chile | 2 | 1997 | 17 | 0.040 |
Why?
|
| Extracellular Matrix Proteins | 1 | 1999 | 144 | 0.040 |
Why?
|
| Cuspid | 2 | 2009 | 6 | 0.040 |
Why?
|
| South Carolina | 1 | 2005 | 2752 | 0.040 |
Why?
|
| Seroepidemiologic Studies | 1 | 2018 | 41 | 0.040 |
Why?
|
| Minisatellite Repeats | 2 | 2009 | 16 | 0.040 |
Why?
|
| Infusions, Subcutaneous | 1 | 2018 | 5 | 0.040 |
Why?
|
| Angioplasty, Balloon, Laser-Assisted | 1 | 1998 | 2 | 0.040 |
Why?
|
| Organic Chemicals | 1 | 1998 | 77 | 0.040 |
Why?
|
| Urban Population | 2 | 1997 | 255 | 0.040 |
Why?
|
| Melanoma | 1 | 1981 | 335 | 0.040 |
Why?
|
| Analysis of Variance | 3 | 1996 | 1040 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2018 | 334 | 0.040 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2018 | 381 | 0.040 |
Why?
|
| beta-Lactamases | 1 | 1997 | 33 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2020 | 446 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2015 | 226 | 0.040 |
Why?
|
| Coronary Artery Bypass | 1 | 1998 | 218 | 0.030 |
Why?
|
| Mixed Connective Tissue Disease | 2 | 1999 | 9 | 0.030 |
Why?
|
| Ryanodine Receptor Calcium Release Channel | 1 | 1997 | 56 | 0.030 |
Why?
|
| Beryllium | 1 | 1996 | 5 | 0.030 |
Why?
|
| Premenopause | 1 | 1996 | 57 | 0.030 |
Why?
|
| Africa | 1 | 1995 | 41 | 0.030 |
Why?
|
| Body Mass Index | 2 | 2010 | 867 | 0.030 |
Why?
|
| Cell Degranulation | 1 | 2015 | 24 | 0.030 |
Why?
|
| Virus Activation | 1 | 2015 | 15 | 0.030 |
Why?
|
| Dopamine | 1 | 2018 | 474 | 0.030 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2015 | 73 | 0.030 |
Why?
|
| Viral Load | 1 | 2015 | 127 | 0.030 |
Why?
|
| Papua New Guinea | 1 | 1995 | 6 | 0.030 |
Why?
|
| Research Design | 1 | 1999 | 729 | 0.030 |
Why?
|
| Recurrence | 1 | 1998 | 948 | 0.030 |
Why?
|
| Monocytes | 1 | 1996 | 210 | 0.030 |
Why?
|
| Immunity, Innate | 1 | 1995 | 156 | 0.030 |
Why?
|
| Gene Pool | 1 | 1994 | 1 | 0.030 |
Why?
|
| Selection, Genetic | 1 | 1995 | 49 | 0.030 |
Why?
|
| Emigration and Immigration | 1 | 1994 | 33 | 0.030 |
Why?
|
| Thyroid Gland | 2 | 1989 | 67 | 0.030 |
Why?
|
| Prevalence | 1 | 1999 | 1619 | 0.030 |
Why?
|
| Kinetics | 1 | 2015 | 1047 | 0.030 |
Why?
|
| Genes, MHC Class I | 1 | 1994 | 14 | 0.030 |
Why?
|
| Glomerulonephritis, IGA | 1 | 1994 | 12 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 1994 | 219 | 0.030 |
Why?
|
| Base Sequence | 1 | 1995 | 1015 | 0.030 |
Why?
|
| Korea | 2 | 2006 | 13 | 0.030 |
Why?
|
| Bacterial Capsules | 5 | 1996 | 8 | 0.030 |
Why?
|
| Language | 1 | 1994 | 120 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2019 | 2007 | 0.030 |
Why?
|
| Immunoglobulin lambda-Chains | 1 | 1993 | 10 | 0.030 |
Why?
|
| Kenya | 1 | 2013 | 26 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 1994 | 397 | 0.030 |
Why?
|
| Hemagglutination Tests | 3 | 1997 | 16 | 0.030 |
Why?
|
| Coinfection | 1 | 2013 | 30 | 0.030 |
Why?
|
| Gene Expression | 1 | 2015 | 770 | 0.030 |
Why?
|
| Registries | 1 | 2016 | 733 | 0.030 |
Why?
|
| Placenta | 1 | 2013 | 101 | 0.030 |
Why?
|
| Multilocus Sequence Typing | 1 | 2011 | 7 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 1990 | 629 | 0.020 |
Why?
|
| Hemoglobin, Sickle | 1 | 2011 | 22 | 0.020 |
Why?
|
| Ribonucleoproteins, Small Nuclear | 1 | 1991 | 11 | 0.020 |
Why?
|
| Ribonucleoproteins | 1 | 1991 | 19 | 0.020 |
Why?
|
| Epiglottitis | 3 | 1989 | 6 | 0.020 |
Why?
|
| Lod Score | 1 | 1991 | 14 | 0.020 |
Why?
|
| Immunization | 3 | 1986 | 86 | 0.020 |
Why?
|
| Malaysia | 1 | 1990 | 6 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2011 | 180 | 0.020 |
Why?
|
| HLA-D Antigens | 2 | 2004 | 20 | 0.020 |
Why?
|
| Time Factors | 2 | 2009 | 4655 | 0.020 |
Why?
|
| China | 1 | 1990 | 138 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 1996 | 1293 | 0.020 |
Why?
|
| Molecular Epidemiology | 1 | 2009 | 16 | 0.020 |
Why?
|
| Tooth Crown | 1 | 2009 | 2 | 0.020 |
Why?
|
| Base Pairing | 1 | 2009 | 15 | 0.020 |
Why?
|
| Torque | 1 | 2009 | 34 | 0.020 |
Why?
|
| Recombination, Genetic | 2 | 1980 | 62 | 0.020 |
Why?
|
| Rotation | 1 | 2009 | 58 | 0.020 |
Why?
|
| Antigenic Variation | 1 | 1988 | 1 | 0.020 |
Why?
|
| Gene Rearrangement | 1 | 1988 | 19 | 0.020 |
Why?
|
| Smoking | 1 | 1997 | 1452 | 0.020 |
Why?
|
| Stress, Mechanical | 1 | 2009 | 208 | 0.020 |
Why?
|
| Puerto Rico | 1 | 2008 | 31 | 0.020 |
Why?
|
| Acanthosis Nigricans | 1 | 2008 | 4 | 0.020 |
Why?
|
| Panniculitis | 1 | 2008 | 7 | 0.020 |
Why?
|
| Body Fat Distribution | 1 | 2008 | 8 | 0.020 |
Why?
|
| Age of Onset | 2 | 1999 | 188 | 0.020 |
Why?
|
| Hirsutism | 1 | 2008 | 6 | 0.020 |
Why?
|
| Contracture | 1 | 2008 | 15 | 0.020 |
Why?
|
| Mexico | 2 | 2002 | 38 | 0.020 |
Why?
|
| Hypertriglyceridemia | 1 | 2008 | 21 | 0.020 |
Why?
|
| Connectin | 2 | 1999 | 14 | 0.020 |
Why?
|
| Facial Dermatoses | 1 | 2008 | 14 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2008 | 196 | 0.020 |
Why?
|
| Exanthema | 1 | 2008 | 30 | 0.020 |
Why?
|
| Myelin-Associated Glycoprotein | 1 | 1987 | 7 | 0.020 |
Why?
|
| Fatty Liver | 1 | 2008 | 97 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2009 | 333 | 0.020 |
Why?
|
| Streptococcus pyogenes | 1 | 1987 | 20 | 0.020 |
Why?
|
| Immunization, Secondary | 3 | 1996 | 17 | 0.020 |
Why?
|
| Pregnancy | 1 | 2013 | 2334 | 0.020 |
Why?
|
| Periodontal Ligament | 1 | 2006 | 16 | 0.020 |
Why?
|
| Forecasting | 1 | 2008 | 277 | 0.020 |
Why?
|
| Pneumococcal Vaccines | 2 | 1997 | 30 | 0.020 |
Why?
|
| Calcinosis | 1 | 2008 | 241 | 0.020 |
Why?
|
| Random Allocation | 1 | 2007 | 442 | 0.020 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 1986 | 9 | 0.020 |
Why?
|
| Maxilla | 1 | 2006 | 63 | 0.020 |
Why?
|
| Campylobacter fetus | 1 | 1986 | 1 | 0.020 |
Why?
|
| Insulin Resistance | 1 | 2008 | 241 | 0.020 |
Why?
|
| HLA-B27 Antigen | 1 | 1985 | 4 | 0.020 |
Why?
|
| Hepatitis B | 1 | 1986 | 42 | 0.020 |
Why?
|
| Purpura, Thrombocytopenic | 1 | 1985 | 3 | 0.020 |
Why?
|
| Rifampin | 1 | 1986 | 45 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2009 | 689 | 0.020 |
Why?
|
| False Negative Reactions | 1 | 2005 | 63 | 0.020 |
Why?
|
| Proteins | 1 | 2009 | 474 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2005 | 95 | 0.020 |
Why?
|
| Scleroderma, Diffuse | 1 | 2005 | 25 | 0.020 |
Why?
|
| Chromosomes | 1 | 1985 | 17 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2005 | 132 | 0.020 |
Why?
|
| Amino Acid Sequence | 2 | 1999 | 1083 | 0.020 |
Why?
|
| Celiac Disease | 1 | 1985 | 17 | 0.020 |
Why?
|
| Plant Proteins | 1 | 1985 | 48 | 0.020 |
Why?
|
| Tetanus Toxoid | 2 | 1986 | 11 | 0.010 |
Why?
|
| Regression Analysis | 2 | 1997 | 737 | 0.010 |
Why?
|
| Burkitt Lymphoma | 1 | 1984 | 18 | 0.010 |
Why?
|
| Laryngitis | 1 | 1984 | 12 | 0.010 |
Why?
|
| Blood Platelets | 1 | 1985 | 284 | 0.010 |
Why?
|
| Retinitis Pigmentosa | 1 | 1984 | 17 | 0.010 |
Why?
|
| Antigens | 1 | 1984 | 90 | 0.010 |
Why?
|
| HLA-DQ beta-Chains | 1 | 2003 | 5 | 0.010 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2004 | 80 | 0.010 |
Why?
|
| Pertussis Vaccine | 2 | 1984 | 3 | 0.010 |
Why?
|
| Erythrocytes | 1 | 1984 | 137 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 2 | 1985 | 282 | 0.010 |
Why?
|
| alpha 1-Antitrypsin | 2 | 1988 | 61 | 0.010 |
Why?
|
| Sarcoma, Kaposi | 1 | 1983 | 25 | 0.010 |
Why?
|
| Immunoglobulin Joining Region | 1 | 2002 | 3 | 0.010 |
Why?
|
| Guatemala | 1 | 2002 | 9 | 0.010 |
Why?
|
| Indians, Central American | 1 | 2002 | 3 | 0.010 |
Why?
|
| Nervous System Diseases | 1 | 1983 | 142 | 0.010 |
Why?
|
| Choriocarcinoma | 1 | 1982 | 7 | 0.010 |
Why?
|
| Portugal | 1 | 1982 | 7 | 0.010 |
Why?
|
| Teratoma | 1 | 1982 | 22 | 0.010 |
Why?
|
| Testicular Neoplasms | 1 | 1982 | 27 | 0.010 |
Why?
|
| Amyloidosis | 1 | 1982 | 48 | 0.010 |
Why?
|
| Texas | 1 | 1981 | 92 | 0.010 |
Why?
|
| HLA-B8 Antigen | 3 | 1986 | 5 | 0.010 |
Why?
|
| Platelet Membrane Glycoproteins | 1 | 2000 | 19 | 0.010 |
Why?
|
| Splenectomy | 1 | 2000 | 40 | 0.010 |
Why?
|
| Immunoglobulin E | 1 | 2000 | 91 | 0.010 |
Why?
|
| HLA-DR5 Antigen | 2 | 1994 | 3 | 0.010 |
Why?
|
| CREST Syndrome | 1 | 1999 | 5 | 0.010 |
Why?
|
| Thyroglobulin | 1 | 1979 | 17 | 0.010 |
Why?
|
| Indians, North American | 1 | 1999 | 64 | 0.010 |
Why?
|
| Stomach | 1 | 1979 | 80 | 0.010 |
Why?
|
| Diphtheria Toxoid | 1 | 1979 | 5 | 0.010 |
Why?
|
| Isoantigens | 1 | 1979 | 26 | 0.010 |
Why?
|
| Neutrophil Activation | 1 | 1998 | 3 | 0.010 |
Why?
|
| Hemagglutination Inhibition Tests | 2 | 1994 | 10 | 0.010 |
Why?
|
| Myositis, Inclusion Body | 1 | 1998 | 5 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 1979 | 305 | 0.010 |
Why?
|
| Trichloroethylene | 1 | 1998 | 41 | 0.010 |
Why?
|
| Family Health | 1 | 1998 | 83 | 0.010 |
Why?
|
| Chromosomes, Bacterial | 1 | 1997 | 7 | 0.010 |
Why?
|
| Jews | 1 | 1997 | 7 | 0.010 |
Why?
|
| Calmodulin-Binding Proteins | 1 | 1997 | 6 | 0.010 |
Why?
|
| Reference Values | 1 | 1998 | 579 | 0.010 |
Why?
|
| Finland | 2 | 1988 | 13 | 0.010 |
Why?
|
| Head and Neck Neoplasms | 1 | 1982 | 561 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 1998 | 271 | 0.010 |
Why?
|
| Immunization Schedule | 1 | 1996 | 25 | 0.010 |
Why?
|
| Virginia | 1 | 1996 | 45 | 0.010 |
Why?
|
| Cycloheximide | 1 | 1996 | 50 | 0.010 |
Why?
|
| Leukemia, Myeloid | 1 | 1996 | 39 | 0.010 |
Why?
|
| Pneumococcal Infections | 1 | 1996 | 30 | 0.010 |
Why?
|
| Software | 2 | 1989 | 418 | 0.010 |
Why?
|
| gamma-Globulins | 1 | 1995 | 8 | 0.010 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 1995 | 17 | 0.010 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 1995 | 24 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 1996 | 251 | 0.010 |
Why?
|
| Absorptiometry, Photon | 1 | 1995 | 83 | 0.010 |
Why?
|
| Testosterone | 1 | 1995 | 96 | 0.010 |
Why?
|
| Radioimmunoassay | 2 | 1986 | 164 | 0.010 |
Why?
|
| Body Composition | 1 | 1995 | 119 | 0.010 |
Why?
|
| Rural Population | 2 | 1990 | 398 | 0.010 |
Why?
|
| Interleukin-4 | 1 | 1994 | 69 | 0.010 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 1994 | 41 | 0.010 |
Why?
|
| Blotting, Western | 1 | 1997 | 954 | 0.010 |
Why?
|
| Osteoporosis | 1 | 1995 | 88 | 0.010 |
Why?
|
| HLA-DR3 Antigen | 2 | 1985 | 7 | 0.010 |
Why?
|
| Circadian Rhythm | 1 | 1995 | 218 | 0.010 |
Why?
|
| Fractures, Bone | 1 | 1995 | 132 | 0.010 |
Why?
|
| Estradiol | 1 | 1995 | 176 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 1996 | 852 | 0.010 |
Why?
|
| Family | 1 | 1996 | 293 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 1997 | 1054 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 1994 | 241 | 0.010 |
Why?
|
| Nuclear Family | 1 | 1993 | 16 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 1991 | 67 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 1997 | 2279 | 0.010 |
Why?
|
| Receptors, Cholinergic | 1 | 1990 | 30 | 0.010 |
Why?
|
| India | 1 | 1990 | 41 | 0.010 |
Why?
|
| Muscles | 1 | 1990 | 158 | 0.010 |
Why?
|
| Minnesota | 1 | 1989 | 27 | 0.010 |
Why?
|
| Infant, Newborn | 2 | 1986 | 2455 | 0.010 |
Why?
|
| Simplexvirus | 1 | 1988 | 26 | 0.000 |
Why?
|
| Capillaries | 1 | 1988 | 105 | 0.000 |
Why?
|
| Cell Wall | 1 | 1987 | 21 | 0.000 |
Why?
|
| Antigens, Surface | 1 | 1987 | 71 | 0.000 |
Why?
|
| Cellulitis | 1 | 1986 | 13 | 0.000 |
Why?
|
| HLA-A1 Antigen | 1 | 1986 | 1 | 0.000 |
Why?
|
| Missouri | 1 | 1986 | 44 | 0.000 |
Why?
|
| Epidemiologic Methods | 1 | 1986 | 83 | 0.000 |
Why?
|
| Complement System Proteins | 1 | 1986 | 135 | 0.000 |
Why?
|
| Dermatoglyphics | 1 | 1985 | 2 | 0.000 |
Why?
|
| Enzymes | 1 | 1985 | 25 | 0.000 |
Why?
|
| Raynaud Disease | 1 | 1985 | 24 | 0.000 |
Why?
|
| Epiglottis | 1 | 1984 | 11 | 0.000 |
Why?
|
| HLA-A Antigens | 1 | 1984 | 8 | 0.000 |
Why?
|
| HLA-B35 Antigen | 1 | 1983 | 6 | 0.000 |
Why?
|
| Clone Cells | 1 | 1981 | 67 | 0.000 |
Why?
|
| France | 1 | 1977 | 26 | 0.000 |
Why?
|